Skip to main content
Dantes.io Logo
Dantes.io

Best resources to learnObesity Medicine & GLP-1 Drugs

Study sheet

Obesity medicine treats excess body weight as a chronic disease. You will learn how appetite and energy balance are regulated, how GLP-1 drugs such as semaglutide and tirzepatide work, their benefits and side effects, and how they compare with lifestyle and surgical options.

8 resources · · How we curate

📚Books(2)

bookPaid

Burn: New Research Blows the Lid Off How We Really Burn Calories, Lose Weight, and Stay Healthy

An evolutionary anthropologist presents doubly labeled water studies of energy use in the Hadza and other populations. He explains the constrained energy expenditure model, why exercise alone rarely produces lasting weight loss, and how diet and metabolism interact.

beginner🇬🇧
bookPaid

The Hungry Brain: Outsmarting the Instincts That Make Us Overeat

A neuroscientist explains how the brain controls appetite and body fat, covering the hypothalamus, leptin, reward and satiety signals, and why modern food environments lead to overeating. The book is grounded in obesity research and gives background for why appetite-targeting drugs work. This is the best book-length introduction to how appetite and body weight are regulated.

beginner🇬🇧

🌐Websites(1)

website

Canadian Adult Obesity Clinical Practice Guideline

This one free source covers the whole topic: medications, lifestyle treatment and surgery, all judged against the same evidence standard. Regularly updated clinical guideline in 19 chapters covering the science of obesity, assessment, nutrition, physical activity, psychological therapy, medications (updated 2025 with semaglutide and tirzepatide) and bariatric surgery, with graded evidence and plain-language key messages.

intermediate🇬🇧

📄Papers(4)

paper

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial)

Cardiovascular outcomes trial of semaglutide 2.4 mg in 17,604 adults with heart disease and overweight or obesity but no diabetes. It found 20% fewer heart attacks, strokes and cardiovascular deaths, the first such result for an obesity drug. SELECT is the key trial showing they reduce serious health events, which is essential for judging benefits beyond the scale.

advanced🇬🇧
paper

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 Trial)

This is the original evidence for the most effective approved obesity drug. Read alongside STEP 1, it shows how a dual GIP/GLP-1 agonist compares with semaglutide alone. 72-week phase 3 trial of tirzepatide, a drug that activates both GIP and GLP-1 receptors, in 2,539 adults without diabetes. Mean weight loss was 15% to 20.9% depending on dose, versus 3.1% with placebo, with side-effect data for each dose.

advanced🇬🇧
paper

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial)

This is the original evidence for semaglutide's weight-loss effect, and nearly every guideline and review cites it. The main 68-week randomized controlled trial of semaglutide 2.4 mg in 1,961 adults without diabetes. Mean weight loss was 14.9% versus 2.4% with placebo. The paper also reports gastrointestinal side effects and why participants stopped treatment.

advanced🇬🇧
paper

Definition and Diagnostic Criteria of Clinical Obesity (Lancet Diabetes & Endocrinology Commission)

This is the current reference framework for treating obesity as a disease. 2025 consensus report from 58 international experts separating preclinical obesity (excess fat, organs working normally) from clinical obesity (a chronic illness with organ dysfunction). It sets diagnostic criteria beyond BMI and explains what each diagnosis means for treatment.

intermediate🇬🇧

🎙️Podcasts(1)

podcast

Daniel Drucker: Illuminating the GLP-1 Drugs' Break Out (Ground Truths)

This is the best free, non-technical explanation of how GLP-1 drugs work, given by someone who helped discover the biology. It covers mechanism, muscle loss and stopping treatment without influencer or telehealth bias. It dates from April 2024, so it predates some newer trials, but the explanation of how the drugs work still holds. Eric Topol interviews Daniel Drucker, one of the scientists who discovered how GLP-1 works, about how the drugs reduce appetite through the brain, lean-mass loss, what happens after stopping, and the anti-inflammatory effects linked to heart, kidney and liver benefits. A free transcript is included.

beginner🇬🇧
Share this topic

More in Medical Sciences

See all 15 topics in Medical Sciences →

Frequently Asked Questions

What are the best free resources to learn Obesity Medicine & GLP-1 Drugs?

Dantes has curated 8 resources for Obesity Medicine & GLP-1 Drugs, including 2 books, 1 websites, 4 papers, 1 podcasts. All resources are hand-picked for quality — no algorithmic filler. Browse the full list above to find the format that works best for you.

Is Obesity Medicine & GLP-1 Drugs hard to learn?

Obesity Medicine & GLP-1 Drugs is approachable at the beginner level — there are resources here specifically for those starting from scratch. As you progress, intermediate and advanced material is also available to take your skills further.

What types of Obesity Medicine & GLP-1 Drugs learning resources are available on Dantes?

For Obesity Medicine & GLP-1 Drugs, Dantes has curated 2 books, 1 websites, 4 papers, 1 podcasts. Each resource type serves a different learning style: videos and YouTube for visual learners, books for depth, courses for structured progression, and websites for quick reference.

How does Dantes select Obesity Medicine & GLP-1 Drugs resources?

Dantes is an algorithm-free learning directory. Resources are hand-curated based on quality, accuracy, and usefulness — not engagement metrics or paid placements. The goal is to surface the best learning material for Obesity Medicine & GLP-1 Drugs, whether it's a free YouTube series, a classic textbook, or an open courseware from a top university.

Go deeper

Test your understanding of Obesity Medicine & GLP-1 Drugs

Explain it out loud. An AI tutor listens and asks questions that expose gaps you didn't know you had.